Please ensure Javascript is enabled for purposes of website accessibility

Dynavax Stock Soars 26.4% Today on COVID-19 Vaccine Hopes

By Todd Campbell – Updated May 29, 2020 at 4:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's vaccine partner made positive comments about its progress today.

What happened

Shares of Dynavax Technologies (DVAX 1.36%) jumped 26.4% on Friday following comments by researchers at Sinovac, a Chinese drug developer that's collaborating with Dynavax on a COVID-19 vaccine.

So what

In April, Dynavax and Sinovac agreed to collaborate to develop a vaccine for COVID-19. Dynavax is contributing an adjuvant that can boost immune responses in vaccinated patients, while Sinovac is contributing an inactivated coronavirus vaccine candidate. 

A doctor talking through a megaphone.

Image source: Getty Images.

In a Sky News article about Sinovac's progress published on Friday, Sinovac researcher Luo Baishan was quoted as saying its vaccine would likely pan out, responding: "Yes, yes. It must be successful ... 99% [sure]," when asked by reporters about the likelihood of its development producing an effective vaccine.

But Helen Yang, a senior director of investor relations at the healthcare company, struck a more cautious tone. When asked a similar question, she replied: "It's very hard to say, very difficult to say at the moment. There are uncertainties, but the data: so far, so good."

The race for a COVID-19 vaccine is significant because there have been over 5.8 million cases globally, including over 360,000 deaths, according to the Johns Hopkins Coronavirus Resource Center.

Now what

Dynavax's adjuvant is a synthetic form of DNA that is already used in Dynavax's approved hepatitis B vaccine, Heplisav-B, but that doesn't guarantee it will be similarly effective in helping Sinovac's COVID-19 vaccine succeed. 

Investors should also remember that Sinovac's vaccine is only in the earlier stages of development, and while it's shown promise in primates, more research in humans is necessary. Yang expects it to be "many months" before its current stage of research is complete, enabling Sinovac to advance it into the next stage of research involving more people. 

Their vaccine isn't the only one under development, either. Many companies are conducting their own research, including AstraZeneca (AZN -0.13%), which is working with Oxford University, and Moderna (MRNA 0.15%), which is advancing its vaccine candidate, mRNA-1273, into phase 2 trials in the United States. Because of the flurry of activity and uncertainty, investors ought to approach Dynavax cautiously.

 

Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dynavax Technologies Corporation Stock Quote
Dynavax Technologies Corporation
DVAX
$10.44 (1.36%) $0.14
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$54.84 (-0.13%) $0.07
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$118.25 (0.15%) $0.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.